Tlr9 Stocks List

Tlr9 Stocks Recent News

Date Stock Title
Nov 8 DVAX Dynavax rises 11% on Q3 bottom line beat, 2024 positive net income expectation
Nov 8 DVAX Dynavax Technologies Corp (DVAX) Q3 2024 Earnings Call Highlights: Record Hep B Sales and ...
Nov 8 DVAX Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript
Nov 8 DVAX Dynavax Technologies Corporation (DVAX) Q3 2024 Earnings Call Transcript
Nov 8 DVAX Dynavax Technologies Corporation 2024 Q3 - Results - Earnings Call Presentation
Nov 7 DVAX Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
Nov 7 DVAX Dynavax Technologies: Q3 Earnings Snapshot
Nov 7 DVAX Dynavax announces $200M share repurchase program
Nov 7 DVAX Dynavax GAAP EPS of $0.12 beats by $0.01, revenue of $80.63M misses by $3.54M
Nov 7 DVAX Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
Nov 7 DVAX Dynavax Announces $200 Million Share Repurchase Program
Nov 7 ABUS Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Nov 7 ABUS Q3 2024 Arbutus Biopharma Corp Earnings Call
Nov 6 DVAX Dynavax Q3 2024 Earnings Preview
Nov 6 ABUS Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
Nov 6 ABUS Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Nov 6 ABUS Arbutus: Q3 Earnings Snapshot
Nov 6 ABUS Arbutus Biopharma GAAP EPS of -$0.10 misses by $0.01, revenue of $1.34M misses by $0.53M
Nov 6 ABUS Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 5 ABUS Arbutus Biopharma Q3 2024 Earnings Preview
Tlr9

Toll-like receptor 9 is a protein that in humans is encoded by the TLR9 gene. TLR9 has also been designated as CD289 (cluster of differentiation 289). It is a member of the toll-like receptor (TLR) family. TLR9 is an important receptor expressed in immune system cells including dendritic cells, macrophages, natural killer cells, and other antigen presenting cells. TLR9 preferentially binds DNA present in bacteria and viruses, and triggers signaling cascades that lead to a pro-inflammatory cytokine response. Cancer, infection, and tissue damage can all modulate TLR9 expression and activation. TLR9 is also an important factor in autoimmune diseases, and there is active research into synthetic TLR9 agonists and antagonists that help regulate autoimmune inflammation.

Browse All Tags